Login to Your Account



SALIX: ACCESS FOR PATIENTS LATER THIS YEAR

Pharming's Ruconest wins FDA nod in crowded orphan HAE market

By Jennifer Boggs and Cormac Sheridan
Staff Writers

Thursday, July 17, 2014
As expected, the FDA cleared for marketing Wednesday recombinant human C1 esterase inhibitor Ruconest (conestat alpha) for use in acute attacks of hereditary angioedema (HAE), news that should bring an immediate lift to developer Pharming Group NV.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription